Familial Hypertrophic Cardiomyopathy: Diagnosis and Management

References

• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation. 1995;92:785–789. doi:10.1161/01.cir.92.4.785
   PubMed Web of Science ®Google Scholar
• Maron BJ. Clinical Course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:1977. doi:10.1056/NEJMc1812159
   PubMed Web of Science ®Google Scholar
• Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116:14–18. doi:10.1016/j.amjmed.2003.05.009
   PubMed Web of Science ®Google Scholar
• Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:390–414. doi:10.1016/j.jacc.2021.11.021
   PubMedGoogle Scholar
• Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387–1398. doi:10.1161/CIRCULATIONAHA.117.033200
   PubMed Web of Science ®Google Scholar
• Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2020;142:e533–e557. doi:10.1161/CIR.0000000000000938
   PubMed Web of Science ®Google Scholar
• Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59:183–184. doi:10.1016/s0002-9149(87)80107-8
   PubMed Web of Science ®Google Scholar
• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–770. doi:10.1161/CIRCRESAHA.117.311059
   PubMed Web of Science ®Google Scholar
• Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590–1595. doi:10.1016/s0735-1097(99)00039-x
   PubMed Web of Science ®Google Scholar
• Siontis KC, Ommen SR, Geske JB. Sex, survival, and cardiomyopathy: differences between men and women with hypertrophic cardiomyopathy. J Am Heart Assoc. 2019;8:e014448. doi:10.1161/JAHA.119.014448
   PubMed Web of Science ®Google Scholar
• Geske JB, Ong KC, Siontis KC, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38:3434–3440. doi:10.1093/eurheartj/ehx527
   PubMedGoogle Scholar
• Butters A, Lakdawala NK, Ingles J. Sex differences in hypertrophic cardiomyopathy: interaction with genetics and environment. Curr Heart Fail Rep. 2021;18:264–273. doi:10.1007/s11897-021-00526-x
   PubMed Web of Science ®Google Scholar
• Patlolla SH, Schaff HV, Nishimura RA, et al. Sex and race disparities in hypertrophic cardiomyopathy: unequal implantable cardioverter-defibrillator use during hospitalization. Mayo Clin Proc. 2022;97:507–518. doi:10.1016/j.mayocp.2021.07.022
   PubMed Web of Science ®Google Scholar
• Pedram A, Razandi M, Lubahn D, et al. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149:3361–3369. doi:10.1210/en.2008-0133
   PubMed Web of Science ®Google Scholar
• Haines CD, Harvey PA, Luczak ED, et al. Estrogenic compounds are not always cardioprotective and can be lethal in males with genetic heart disease. Endocrinology. 2012;153:4470–4479. doi:10.1210/en.2012-1391
   PubMed Web of Science ®Google Scholar
• Trongtorsak A, Polpichai N, Thangjui S, et al. Gender-related differences in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Pulse. 2021;9:38–46. doi:10.1159/000517618
   PubMed Web of Science ®Google Scholar
• Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension. 2004;44:789–795. doi:10.1161/01.HYP.0000145988.95551.28
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Fleming EJ, Garratt CJ. Mimics of hypertrophic cardiomyopathy - diagnostic clues to aid early identification of phenocopies. Arrhythm Electrophysiol Rev. 2013;2:36–40. doi:10.15420/aer.2013.2.1.36
   PubMedGoogle Scholar
• Hoss S, Habib M, Silver J, et al. Genetic testing for diagnosis of hypertrophic cardiomyopathy mimics: yield and clinical significance. Circ Genom Precis Med. 2020;13:e002748. doi:10.1161/CIRCGEN.119.002748
   PubMed Web of Science ®Google Scholar
• Wilcox NS, Prenner SB, Cevasco M, et al. End stage mitochondrial cardiomyopathy and heart transplantation due to biallelic pathogenic C1QBP variants. Circulation. 2022;15:e003559. doi:10.1161/CIRCGEN.121.003559
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418–428. doi:10.1016/0002-9149(81)90068-0
   PubMed Web of Science ®Google Scholar
• Syed IS, Ommen SR, Breen JF, Tajik AJ. Hypertrophic cardiomyopathy: identification of morphological subtypes by echocardiography and cardiac magnetic resonance imaging. JACC Cardiovasc Imaging. 2008;1:377–379. doi:10.1016/j.jcmg.2008.02.008
   PubMed Web of Science ®Google Scholar
• Turer AT, Samad Z, Valente AM, et al. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12:131–139. doi:10.1093/ejechocard/jeq163
   PubMed Web of Science ®Google Scholar
• Azechi N, Morita Y, Inoue M, Kuzuyama R, Imataka K. Age-associated morphological change in interventricular septum. Rinsho Byori. 1993;41:285–288. Japanese.
   PubMedGoogle Scholar
• Krasnow N. Subaortic septal bulge simulates hypertrophic cardiomyopathy by angulation of the septum with age, independent of focal hypertrophy. An echocardiographic study. J Am Soc Echocardiogr. 1997;10:545–555. doi:10.1016/s0894-7317(97)70009-9
   PubMed Web of Science ®Google Scholar
• Toth AB, Engel JA, McManus AM, McManus BM. Sigmoidity of the ventricular septum revisited: progression in early adulthood, predominance in men, and Independence from cardiac mass. Am J Cardiovasc Pathol. 1988;2:211–223.
   PubMedGoogle Scholar
• Canepa M, Pozios I, Vianello PF, et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart. 2016;102:1087–1094. doi:10.1136/heartjnl-2015-308764
   PubMed Web of Science ®Google Scholar
• Diaz T, Pencina MJ, Benjamin EJ, et al. Prevalence, clinical correlates, and prognosis of discrete upper septal thickening on echocardiography: the Framingham Heart Study. Echocardiography. 2009;26:247–253. doi:10.1111/j.1540-8175.2008.00806.x
   PubMed Web of Science ®Google Scholar
• Mendez C, Soler R, Rodríguez E, et al. Differential diagnosis of thickened myocardium: an illustrative MRI review. Insights Imaging. 2018;9:695–707. doi:10.1007/s13244-018-0655-9
   PubMed Web of Science ®Google Scholar
• Valente AM, Lakdawala NK, Powell AJ, et al. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013;6:230–237. doi:10.1161/CIRCGENETICS.113.000037
   PubMedGoogle Scholar
• Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–1257. doi:10.1056/NEJM199804303381802
   PubMed Web of Science ®Google Scholar
• Millat G, Bouvagnet P, Chevalier P, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53:261–267. doi:10.1016/j.ejmg.2010.07.007
   PubMed Web of Science ®Google Scholar
• Kaski JP, Syrris P, Esteban MTT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:436–441. doi:10.1161/CIRCGENETICS.108.821314
   PubMedGoogle Scholar
• Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson heart study cohorts. Am J Hum Genet. 2012;91:513–519. doi:10.1016/j.ajhg.2012.07.017
   PubMed Web of Science ®Google Scholar
• Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019;9:878. doi:10.3390/biom9120878
   PubMed Web of Science ®Google Scholar
• Littler WA. Twin studies in hypertrophic cardiomyopathy. Br Heart J. 1972;34:1147–1151. doi:10.1136/hrt.34.11.1147
   PubMedGoogle Scholar
• Repetti GG, Kim Y, Pereira AC, et al. Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proc Natl Acad Sci USA. 2021;118. doi:10.1073/pnas.2021717118
   PubMed Web of Science ®Google Scholar
• Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:449–457. doi:10.1016/j.jacc.2013.03.062
   PubMed Web of Science ®Google Scholar
• Fumagalli C, Maurizi N, Day SM, et al. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5:65–72. doi:10.1001/jamacardio.2019.4268
   PubMed Web of Science ®Google Scholar
• Nollet EE, Westenbrink BD, de Boer RA, Kuster DWD, van der Velden J. Unraveling the genotype-phenotype relationship in hypertrophic cardiomyopathy: obesity-related cardiac defects as a major disease modifier. J Am Heart Assoc. 2020;9:e018641. doi:10.1161/JAHA.120.018641
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu B. Clinical significance of overweight in patients with hypertrophic cardiomyopathy: a retrospective cohort study. Medicine. 2021;100:e27445. doi:10.1097/MD.0000000000027445
   PubMed Web of Science ®Google Scholar
• Klempfner R, Kamerman T, Schwammenthal E, et al. Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol. 2015;22:13–19. doi:10.1177/2047487313501277
   PubMed Web of Science ®Google Scholar
• Limongelli G, Monda E, D’Aponte A, et al. Combined effect of Mediterranean diet and aerobic exercise on weight loss and clinical status in obese symptomatic patients with hypertrophic cardiomyopathy. Heart Fail Clin. 2021;17:303–313. doi:10.1016/j.hfc.2021.01.003
   PubMed Web of Science ®Google Scholar
• Petto J, DE Oliveira EC, DE Almeida RVA, et al. Reverse myocardial remodeling in hypertrophic cardiomyopathy: little explored benefit of exercise. Int J Exerc Sci. 2021;14:1018–1026.
   Google Scholar
• Saberi S, Wheeler M, Day SM. Exercise for patients with hypertrophic cardiomyopathy-reply. JAMA. 2017;318:481–482. doi:10.1001/jama.2017.8201
   PubMed Web of Science ®Google Scholar
• Kwon DH, Smedira NG, Popovic ZB, et al. Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using three-dimensional multimodality imaging. Heart. 2009;95:1784–1791. doi:10.1136/hrt.2009.166777
   PubMed Web of Science ®Google Scholar
• Critoph CH, Pantazis A, Tome Esteban MT, et al. The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Open Heart. 2014;1:e000176. doi:10.1136/openhrt-2014-000176
   PubMedGoogle Scholar
• Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–47. doi:10.1161/CIRCULATIONAHA.110.985812
   PubMed Web of Science ®Google Scholar
• Makavos G, Κairis C, Tselegkidi M-E, et al. Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. Heart Fail Rev. 2019;24:439–459. doi:10.1007/s10741-019-09775-4
   PubMed Web of Science ®Google Scholar
• Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251–1258. doi:10.1016/j.jacc.2005.01.012
   PubMed Web of Science ®Google Scholar
• Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617–621. doi:10.1126/science.aad3456
   PubMed Web of Science ®Google Scholar
• Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66:1307–1308. doi:10.1016/j.jacc.2015.06.1333
   PubMedGoogle Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58:e44–122. doi:10.1016/j.jacc.2011.08.007
   PubMed Web of Science ®Google Scholar
• Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–476. doi:10.1016/j.jacc.2005.02.090
   PubMed Web of Science ®Google Scholar
• Day SM, Tardiff JC, Ostap EM. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. J Clin Invest. 2022;132. doi:10.1172/JCI148557
   Web of Science ®Google Scholar
• Nag S, Trivedi DV, Sarkar SS, et al. The myosin Mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol. 2017;24:525–533. doi:10.1038/nsmb.3408
   PubMed Web of Science ®Google Scholar
• Scellini B, Piroddi N, Dente M, et al. Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle. J Gen Physiol. 2021;153. doi:10.1085/jgp.202012789
   PubMed Web of Science ®Google Scholar
• Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA. 2018;115:E8143–E8152. doi:10.1073/pnas.1809540115
   PubMed Web of Science ®Google Scholar
• Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170:741–748. doi:10.7326/M18-3016
   PubMed Web of Science ®Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2020;396:759–769. doi:10.1016/S0140-6736(20)31792-X
   PubMed Web of Science ®Google Scholar
• Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021;143:606–608. doi:10.1161/CIRCULATIONAHA.120.052359
   PubMed Web of Science ®Google Scholar
• Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95–108. doi:10.1016/j.jacc.2022.04.048
   PubMed Web of Science ®Google Scholar
• Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64:14142–14152. doi:10.1021/acs.jmedchem.1c01290
   PubMed Web of Science ®Google Scholar
• Malik FI, Robertson LA, Armas DR, et al. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci. 2022;7:763–775. doi:10.1016/j.jacbts.2022.04.008
   PubMedGoogle Scholar
• Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:34–45. doi:10.1016/j.jacc.2022.10.020
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. CY 6031 study will evaluate the effects of treatment with aficamten (CK-3773274) over a 24-week period on cardiopulmonary exercise capacity and health status in patients with symptomatic oHCM (SEQUOIA-HCM). Available from: https://clinicaltrials.gov/ct2/show/NCT05186818. Accessed March 28, 2023.
   Google Scholar
• Del Rio CL, Yadav A, Ferguson BS, et al. Chronic treatment with a mavacamten-like myosin-modulator (MYK-581) blunts disease progression in a mini-pig genetic model of non-obstructed hypertrophic cardiomyopathy: in vivo evidence for improved relaxation and functional reserve. Circulation. 2019;140:A14585–A14585.
   Google Scholar
• Ferguson B, Stern JA, Oldach MS, et al. Acute effects of a mavacamten-like myosin-inhibitor (MYK-581) in a feline model of obstructed hypertrophic cardiomyopathy: evidence of improved ventricular filling (beyond obstruction reprieve). Eur Heart J. 2020;41:ehaa946. doi:10.1093/ehjci/ehaa946.3713
   Google Scholar
• Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649–2660. doi:10.1016/j.jacc.2020.03.064
   PubMed Web of Science ®Google Scholar
• Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021;27:1818–1824. doi:10.1038/s41591-021-01505-4
   PubMed Web of Science ®Google Scholar
• Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021;18:1012–1023. doi:10.1016/j.hrthm.2021.01.019
   PubMed Web of Science ®Google Scholar
• Iavarone M, Monda E, Vritz O, et al. Medical treatment of patients with hypertrophic cardiomyopathy: an overview of current and emerging therapy. Arch Cardiovasc Dis. 2022;115:529–537. doi:10.1016/j.acvd.2022.06.003
   PubMed Web of Science ®Google Scholar
• Packard E, de Feria A, Peshin S, Reza N, Owens AT. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy. Cardiol Ther. 2022;11:491–507. doi:10.1007/s40119-022-00283-5
   PubMed Web of Science ®Google Scholar
• Repetti GG, Toepfer CN, Seidman JG, Seidman CE. Novel therapies for prevention and early treatment of cardiomyopathies. Circ Res. 2019;124:1536–1550. doi:10.1161/CIRCRESAHA.119.313569
   PubMed Web of Science ®Google Scholar
• Prondzynski M, Krämer E, Laufer SD, et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes. Mol Ther Nucleic Acids. 2017;7:475–486. doi:10.1016/j.omtn.2017.05.008
   PubMedGoogle Scholar
• da Rocha AM, Guerrero-Serna G, Helms A, et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol. 2016;99:197–206. doi:10.1016/j.yjmcc.2016.09.004
   PubMed Web of Science ®Google Scholar
• Chai AC, Cui M, Chemello F, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023;11:1.
   Google Scholar
• Iyer AA, Saade D, Bharucha-Goebel D, et al. Ethical challenges for a new generation of early-phase pediatric gene therapy trials. Genet Med. 2021;23:2057–2066. doi:10.1038/s41436-021-01245-3
   PubMed Web of Science ®Google Scholar
• Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:574–579. doi:10.1161/CIRCHEARTFAILURE.109.922872
   PubMed Web of Science ®Google Scholar
• Fowler CC, Helmers MR, Smood B, et al. The modified US heart allocation system improves transplant rates and decreases status upgrade utilization for patients with hypertrophic cardiomyopathy. J Heart Lung Transplant. 2021;40:1181–1190. doi:10.1016/j.healun.2021.06.018
   PubMed Web of Science ®Google Scholar